t
Oxford Biomedica PLC (OXB) announced on 27 May 2026 that Peter Soelkner, its Vice Chair and Independent Non-Executive Director, has been appointed as a Non-Executive Director of Stevanato Group S.p.A. This appointment is effective from 26 May 2026 and was made pursuant to UK Listing Rules 6.4.9R.
| Date | 27 May 2026 |
| Time | 07:00:06 |
| Category | Miscellaneous |
| ID | 7763F |
OXB
Director Declaration
Oxford, UK - 27 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026.
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: [email protected]
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: [email protected]
Mary-Jane Elliott / Sarah Elton-Farr / Angela Gray
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.